Dabrafenib



Combined with:

Indications and Reactions:

Role Indications Reactions
Primary
Metastatic Malignant Melanoma 38.3%
Malignant Melanoma 37.7%
Prophylaxis 4.0%
Hypertension 3.8%
Pain 3.4%
Pyrexia 1.6%
Diabetes Mellitus 1.1%
Epilepsy 1.1%
Atrial Fibrillation 0.9%
Gastritis Prophylaxis 0.9%
Metastases To Central Nervous System 0.9%
Nausea 0.9%
Pancreatitis 0.9%
Colorectal Cancer 0.7%
Dehydration 0.7%
Depression 0.7%
Hypercholesterolaemia 0.7%
Infection 0.7%
Product Used For Unknown Indication 0.7%
Antipsychotic Drug Level Therapeutic 0.4%
Pyrexia 45.3%
Ejection Fraction Decreased 10.9%
Vomiting 7.0%
Basal Cell Carcinoma 4.7%
Skin Toxicity 3.1%
Squamous Cell Carcinoma 3.1%
Urinary Tract Infection 3.1%
Alanine Aminotransferase Increased 2.3%
Respiratory Tract Infection 2.3%
Squamous Cell Carcinoma Of Skin 2.3%
Death 1.6%
Dehydration 1.6%
Diarrhoea 1.6%
Febrile Neutropenia 1.6%
Influenza Like Illness 1.6%
Liver Function Test Abnormal 1.6%
Lower Respiratory Tract Infection 1.6%
Panniculitis 1.6%
Pneumonitis 1.6%
Renal Failure 1.6%
Secondary
Malignant Melanoma 58.2%
Prophylaxis 6.0%
Diabetes Mellitus 4.2%
Hypertension 3.6%
Pyrexia 3.0%
Metastatic Malignant Melanoma 2.7%
Thrombosis Prophylaxis 2.7%
Cough 2.4%
Hypercholesterolaemia 2.4%
Facial Nerve Disorder 2.1%
Hypokalaemia 1.8%
Nausea 1.8%
Epilepsy 1.5%
Febrile Neutropenia 1.5%
Depression 1.2%
Medical Diet 1.2%
Wheezing 1.2%
Back Pain 0.9%
Brain Oedema 0.9%
Dehydration 0.9%
Pyrexia 54.5%
Vomiting 5.7%
Chorioretinopathy 4.5%
Ejection Fraction Decreased 4.5%
Basal Cell Carcinoma 3.4%
Hepatic Enzyme Increased 3.4%
Alanine Aminotransferase Increased 2.3%
Confusional State 2.3%
Hyponatraemia 2.3%
Sepsis 2.3%
Squamous Cell Carcinoma 2.3%
Squamous Cell Carcinoma Of Skin 2.3%
Urinary Tract Infection 2.3%
Atrial Fibrillation 1.1%
Febrile Neutropenia 1.1%
Hepatotoxicity 1.1%
Hypercreatinaemia 1.1%
Hyperglycaemia 1.1%
Malignant Melanoma In Situ 1.1%
Myocardial Infarction 1.1%
Concomitant
Colorectal Cancer 38.5%
Convulsion 7.7%
Hyperglycaemia 7.7%
Hypokalaemia 7.7%
Malignant Melanoma 7.7%
Metastatic Malignant Melanoma 7.7%
Peptic Ulcer 7.7%
Product Used For Unknown Indication 7.7%
Restless Legs Syndrome 7.7%
Death 20.0%
Hypokalaemia 20.0%
Metastases To Central Nervous System 20.0%
Pyrexia 20.0%
Vomiting 20.0%